DMCCB Basel Symposium 2026

In the year of its 125th anniversary, the Swiss Chemical Society celebrates a long tradition of advancing chemistry and fostering scientific exchange. Against this backdrop, the DMCCB Basel Symposium 2026 highlights the transformative role of covalent chemistry in modern drug discovery.

Covalent drugs have re-emerged as powerful therapeutic agents, offering unique advantages in potency, selectivity, and durability of action. With advances in screening technologies, structural biology, and chemical design, covalent chemistry is being applied to a broad range of biological targets once considered difficult or inaccessible. This symposium will bring together leading experts to explore how covalent strategies are reshaping the future of drug discovery.

Speakers:

• Prof. Alberto Dal Corso, University of Milan
• Prof. Matthias Gehringer, Eberhard Karls Universität Tübingen
• Dr. Joanna McGouran, Trinity College Dublin
• Dr. Jeffrey McKenna, Novartis Basel
• Prof. Stephan A. Sieber, TU Munich
• Dr. Andrea Vaupel, Novartis Basel
• Prof. Megan Wright, University of Leeds

Join us on February 5, 2026, at the Biozentrum in Basel, where scientists from medicinal chemistry and chemical biology will present the latest insights and breakthroughs. From innovative screening approaches and mechanistic studies to the development of clinically relevant candidates, this symposium promises a comprehensive overview of the opportunities and challenges in covalent drug discovery.

This event is designed to engage professionals and students alike, fostering dialogue and collaboration across disciplines. Don’t miss this unique opportunity to be part of the discussion driving the next generation of covalent therapeutics.

Organizing Committee
Dr. Christoph Sager, Idorsia
Prof. Nina Hartrampf, University of Zurich
Prof. Dennis Gillingham, University of Basel
Dr. Fides Benfatti, Syngenta